article · Benha Medical Journal
Background: Renal cell carcinoma (RCC) is the most aggressive form of genitourinary malignancy. Tryptophan 2, 3-dioxygenase (TDO2) is the primary enzyme that catalyzes tryptophan to kynurenine. TDO2 is overexpressed in a variety of malignancies. Forkhead box protein 3 (FOXP3) serves as a master regulator in maturation of regulatory T cells (Treg), but recently its expression found in cancer cells. Aim: To elucidate value of FOXP3 and TDO2 expression in RCC. Materials and Methods: In this retrospective study, 66 renal cell carcinomas and 10 cases of non-neoplastic renal tissue were examined. TDO2 and FOXP3 immunohistochemical staining was conducted and evaluated for each case. Results: Significant statistical correlations were observed between TDO2 expression and grade, size, renal sinus invasion, nodal metastasis, and stage (P= 0.03, 0.0001, 0.005, 0.018 and 0.0001 respectively). Tumor FOXP3 expression and grade, renal sinus invasion, renal venous thrombosis, lymph node metastasis, and stage were significantly associated (P= 0.0001, 0.0001, 0.003, 0.001, and 0.0001, respectively). The relationship between FOXP3+ Treg and grade, size, capsular invasion, renal sinus invasion, and stage was significant (P= 0.0001, 0.034, 0.023, 0.033, and 0.002, respectively). The statistical correlations between the expression of TDO2 and tumor FOXP3 and FOXP3+Treg, as well as among the expression of tumor FOXP3 and FOXP3+Treg, were highly significant (P value < 0.01). Conclusion: TDO2 and FOXP3 may have role in tumorigenesis and progression of RCC and could be potential markers for targeted therapy.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/bmfj.2024.332353.2242
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.